Sysmex Corp. (6869) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.82 M

Shareholding (Mar 2025)

FII

0.00%

Held by 3 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 11.89%

Healthy long term growth as Net Sales has grown by an annual rate of 10.99%
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 47.97

Negative results in Jun 25

With ROE of 12.00%, it has a attractive valuation with a 3.18 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 1,229,001 Million (Large Cap)

P/E

27.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.07

Return on Equity

10.65%

Price to Book

2.66

Revenue and Profits:

Net Sales:

105,731 Million

(Quarterly Results - Jun 2025)

Net Profit:

4,476 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-22.67%

6 Months

-38.85%

1 Year

-52.12%

2 Years

-44.27%

3 Years

-83.35%

4 Years

-89.63%

5 Years

-87.29%

Sysmex Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Sysmex Corp. Stock Hits Day Low Amid Price Pressure, Falling to JPY 1,711.50

Sysmex Corp. faced a notable decline in its stock price, reflecting ongoing financial challenges. The company reported a net sales decrease and has underperformed compared to the Japan Nikkei 225 index. Key financial metrics indicate a return on equity of 10.65% and a market capitalization of JPY 1,229,001 million.

Sysmex Corp. Stock Hits Day Low Amid Price Pressure, Closes at JPY 1,727.00

Sysmex Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant stock decline today, marking a continued trend of underperformance. Over the past year, the company has experienced substantial losses, with financial metrics indicating challenges in net sales and return on equity. Its market capitalization stands at JPY 1,229,001 million.

Sysmex Corp. Hits Day Low of JPY 1,768.50 Amid Price Pressure

Sysmex Corp. faced a notable decline in its stock price, reflecting a broader trend of underperformance compared to the Japan Nikkei 225 index. The company has experienced significant decreases in its stock over various time frames, alongside a drop in net sales and a high price-to-book ratio, indicating premium trading status.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.99%

EBIT Growth (5y)

10.47%

EBIT to Interest (avg)

47.97

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

1.01

Tax Ratio

31.55%

Dividend Payout Ratio

37.18%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

21.85%

ROE (avg)

11.89%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.18

EV to EBIT

15.94

EV to EBITDA

11.10

EV to Capital Employed

3.44

EV to Sales

2.81

PEG Ratio

Dividend Yield

ROCE (Latest)

21.57%

ROE (Latest)

12.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -5.55% vs 17.40% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -59.25% vs 28.30% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105,731.00",
          "val2": "111,946.00",
          "chgp": "-5.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "20,523.00",
          "val2": "26,454.00",
          "chgp": "-22.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "909.00",
          "val2": "590.00",
          "chgp": "54.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,476.00",
          "val2": "10,984.00",
          "chgp": "-59.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "92.30%",
          "val2": "148.90%",
          "chgp": "-5.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 10.21% vs 12.43% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 7.64% vs 8.86% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "508,643.00",
          "val2": "461,510.00",
          "chgp": "10.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "128,708.00",
          "val2": "113,185.00",
          "chgp": "13.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2,995.00",
          "val2": "2,332.00",
          "chgp": "28.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3,731.00",
          "val2": "149.00",
          "chgp": "-2,604.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "53,576.00",
          "val2": "49,774.00",
          "chgp": "7.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "176.30%",
          "val2": "167.50%",
          "chgp": "0.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

105,731.00

111,946.00

-5.55%

Operating Profit (PBDIT) excl Other Income

20,523.00

26,454.00

-22.42%

Interest

909.00

590.00

54.07%

Exceptional Items

0.00

Consolidate Net Profit

4,476.00

10,984.00

-59.25%

Operating Profit Margin (Excl OI)

92.30%

148.90%

-5.66%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -5.55% vs 17.40% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -59.25% vs 28.30% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

508,643.00

461,510.00

10.21%

Operating Profit (PBDIT) excl Other Income

128,708.00

113,185.00

13.71%

Interest

2,995.00

2,332.00

28.43%

Exceptional Items

-3,731.00

149.00

-2,604.03%

Consolidate Net Profit

53,576.00

49,774.00

7.64%

Operating Profit Margin (Excl OI)

176.30%

167.50%

0.88%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 10.21% vs 12.43% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 7.64% vs 8.86% in Mar 2024

All Annual Results

Company CV

About Sysmex Corp.

Sysmex Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Sysmex Corp.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 11.89%

Negative results in Jun 25

With ROE of 12.00%, it has a attractive valuation with a 3.18 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Sysmex Corp. Stock Hits Day Low Amid Price Pressure, Falling to JPY 1,711.50

Sysmex Corp. Stock Hits Day Low Amid Price Pressure, Closes at JPY 1,727.00

Sysmex Corp. Hits Day Low of JPY 1,768.50 Amid Price Pressure

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Mar'25

About Sysmex Corp.

Company Coordinates